Pharmacovigilance Market to Cross USD 19.4 Billion by 2035, Driven by Growing Focus on Drug Safety

The global pharmacovigilance market is witnessing steadyexpansion as pharmaceutical and biotechnology companies, regulatoryauthorities, healthcare organizations, and contract research organizationsplace greater emphasis on monitoring the safety and effectiveness of medicines.Pharmacovigilance refers to the science and activities associated withdetecting, assessing, understanding, and preventing adverse effects or othermedicine-related problems. As the number of newly developed drugs, biologics,vaccines, and complex therapies increases, the need for comprehensive safetymonitoring throughout the product lifecycle is becoming increasingly important.

The global pharmacovigilance industry was valued at US$ 8.3Bn in 2024. It is projected to grow at a CAGR of 7.9% from 2025 to 2035 andcross US$ 19.4 Bn by the end of 2035. Expansion of pharmaceutical research anddevelopment, increasing regulatory scrutiny, growing adoption of outsourcedpharmacovigilance services, and advances in artificial intelligence and dataanalytics are expected to support market development during the forecastperiod.

Request the SampleReport: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86696

Growing Importance of Drug Safety Monitoring

The growing complexity of modern drug development is one ofthe major factors contributing to demand for pharmacovigilance solutions.Pharmaceutical companies are developing therapies for rare diseases, cancer,autoimmune disorders, neurological conditions, and other complex medicalconditions. These products often require extensive safety monitoring becausetheir effects can vary across patient populations and treatment settings.

Pharmacovigilance activities help identify adverse drug reactionsand safety signals that may not become evident during clinical trials.Continuous monitoring after commercialization enables stakeholders to evaluatereal-world safety information and take appropriate measures when potentialrisks are identified.

The increasing number of medicines entering global marketsis also generating substantial volumes of safety-related data. Healthcareprofessionals, patients, clinical researchers, electronic health records,spontaneous reporting systems, and other sources contribute information thatneeds to be collected, processed, evaluated, and reported.

Regulatory Requirements Strengthen Market Demand

Regulatory compliance remains a key factor shaping thepharmacovigilance market. Regulatory authorities across major pharmaceuticalmarkets require manufacturers to maintain systems for monitoring the safetyprofile of marketed medicines and reporting relevant adverse events.

As pharmaceutical companies operate across multiplecountries, they must manage different reporting requirements, timelines,documentation standards, and regulatory expectations. This complexity hasencouraged companies to invest in specialized pharmacovigilance platforms andservices.

Increasing regulatory attention toward patient safety isalso encouraging organizations to strengthen their adverse-event reporting andsignal-detection capabilities. Companies are increasingly adopting automatedworkflows that help improve data management, case processing, reporting, andcompliance monitoring.

Outsourcing Creates Opportunities for Service Providers

The growing adoption of outsourcing is another importanttrend in the pharmacovigilance market. Pharmaceutical and biotechnologycompanies often collaborate with specialized contract research organizationsand pharmacovigilance service providers to manage safety-related activities.

Outsourcing allows companies to access specializedexpertise, technological infrastructure, trained professionals, and globalregulatory knowledge without developing all capabilities internally. Small andmid-sized pharmaceutical companies, in particular, may benefit from externalpharmacovigilance providers as they expand their product portfolios and enterinternational markets.

Service providers offer a broad range of capabilities,including individual case safety report processing, medical review, aggregatereporting, signal detection, risk management, literature monitoring, safetydatabase management, and regulatory submissions.

Artificial Intelligence and Automation TransformPharmacovigilance

Technological development is creating new opportunities forpharmacovigilance organizations. Artificial intelligence, machine learning,natural language processing, automation, and advanced analytics areincreasingly being explored to improve the management of safety information.

Traditional pharmacovigilance workflows can involve largevolumes of unstructured information. Automated technologies can help identifyrelevant information from scientific literature, classify adverse events,process safety cases, and identify potential signals for further investigation.

Natural language processing can support the extraction ofsafety information from documents and other text-based sources. Machinelearning tools can also assist in identifying patterns across large datasets.These technologies can potentially reduce manual workloads while enablingpharmacovigilance professionals to focus on complex medical assessment anddecision-making.

However, technology adoption also requires appropriatevalidation, data governance, transparency, and regulatory oversight. Companiesare therefore expected to combine automation with human expertise rather thanrelying exclusively on automated systems.

Increasing Clinical Trial Activity Supports Growth

The expansion of clinical research is contributing to theneed for pharmacovigilance services. Pharmaceutical and biotechnology companiesare increasing investments in innovative therapies, including biologics, celland gene therapies, targeted medicines, and personalized treatments.

Clinical trials generate safety information that must besystematically collected and evaluated. Pharmacovigilance teams play animportant role in reviewing adverse events, assessing potential risks,maintaining safety documentation, and supporting regulatory requirements duringclinical development.

As clinical research becomes increasingly global, companiesmay need pharmacovigilance capabilities that can support multiple regions and regulatoryframeworks. This creates opportunities for organizations offering integratedglobal safety management services.

Buy now for expertmarket outlook: https://www.transparencymarketresearch.com/checkout.php?rep_id=86696<ype=S

Regional Outlook

North America represents an important region in the globalpharmacovigilance market due to its established pharmaceutical industry,extensive clinical research activity, sophisticated healthcare infrastructure,and stringent regulatory environment. The presence of major pharmaceuticalcompanies and specialized service providers also supports demand forpharmacovigilance technologies and services.

Europe is another significant market, supported byestablished medicine-safety frameworks and strong emphasis on adverse-eventmonitoring. Pharmaceutical companies operating across European markets requirerobust systems to manage safety information and regulatory reporting.

Asia Pacific is expected to present significant growthopportunities as pharmaceutical manufacturing, clinical research,biotechnology, and healthcare infrastructure continue to expand. Increasingparticipation in international clinical trials and growing awareness of drugsafety are contributing to the adoption of pharmacovigilance services in theregion.

Latin America and the Middle East & Africa are alsodeveloping markets, where increasing pharmaceutical activity, healthcareinvestment, and regulatory modernization can create additional opportunities forpharmacovigilance providers.

Competitive Landscape

Competition in the pharmacovigilance market is shaped bytechnological capabilities, regulatory expertise, global delivery networks,data-management systems, and service portfolios. Companies are focusing onexpanding their safety-monitoring capabilities and incorporating automation andanalytics into existing workflows.

Key Players:

• Accenture
• IQVIA Inc.
• Cognizant
• Linical
• ArisGlobal
• ITClinical
• ICON plc.
• TAKE Solutions Limited
• Parexel International (MA) Corporation
• Wipro
• United BioSource LLC
• Ergomed Group
• Quanticate

Future Outlook

The pharmacovigilance market is expected to continueexpanding as drug development becomes more sophisticated and regulators placecontinued emphasis on patient safety. Increasing volumes of real-world data,growing pharmaceutical R&D investments, expansion of clinical trials, andadoption of technology are likely to influence market development through 2035.

The integration of AI and automation could further changehow safety information is collected, processed, and analyzed. At the same time,the need for qualified pharmacovigilance professionals and medical expertise isexpected to remain important because safety signals require appropriate clinicalinterpretation.

With the global industry valued at US$ 8.3 Bn in 2024 andprojected to cross US$ 19.4 Bn by 2035, the pharmacovigilance market ispositioned for continued development as stakeholders prioritize effectivemedicine-safety monitoring across the pharmaceutical product lifecycle.

Frequently Asked Questions

1. What is the size of the pharmacovigilance market?

The global pharmacovigilance market was valued at US$ 8.3 Bnin 2024 and is projected to cross US$ 19.4 Bn by the end of 2035.

2. What is the expected CAGR of the pharmacovigilancemarket?

The market is projected to expand at a CAGR of 7.9% from2025 to 2035.

3. What is pharmacovigilance?

Pharmacovigilance is the science and activities involved indetecting, assessing, understanding, and preventing adverse effects and othermedicine-related safety problems.

4. What factors are driving the pharmacovigilance market?

Key factors include increasing pharmaceutical R&Dactivity, growing regulatory requirements, rising clinical trial activity,increasing drug approvals, outsourcing of safety-management activities, andadoption of AI and automation.

5. How is artificial intelligence influencingpharmacovigilance?

AI and machine learning can support activities such asadverse-event identification, case processing, literature monitoring, dataclassification, and safety-signal detection, helping organizations manage largevolumes of safety information more efficiently.

More Trending Reports by Transparency Market Research –

Medical Cameras and Microscopes Market - https://www.transparencymarketresearch.com/medical-cameras-market.html

Healthcare Supply Chain Management Market - https://www.transparencymarketresearch.com/healthcare-supply-chain-management-market.html

Neurosurgery Market - https://www.transparencymarketresearch.com/neurosurgery-market.html

MediaContact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com